dm
US$ 29.13
bpc 157 blog BPC-157 Weight Loss: Evidence & Safety 🌟 Discover the Truth About
Description
The TRIUMPH-4 trial, focused on adults with obesity and knee osteoarthritis, reported results showing 28.7% mean weight loss at 68 weeks with the 12 mg dose
Research published in the context of the SURPASS trial program demonstrated that tirzepatide produced dose-dependent HbA1c reductions of 1.24 to 2.58 percent across the studied dose range, and body weight reductions of 5.4 to 11.7 kilograms in patients with type 2 diabetes
Its still a research peptide, and studies are ongoing to confirm its efficacy and safety profile
Dimmeler S, Fleming I, Fisslthaler B, et al
